Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture

Journal of Bone and Mineral Research

Volumn 31, Issue 8, 2016, Pages 1536-1540

  Kim, Seoyoung C ^a   Kim, Dae Hyun ^a,b   Mogun, Helen ^a   Eddings, Wesley ^a   Polinski, Jennifer M ^a,c   Franklin, Jessica M ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c CVS Caremark   (United States)

Author keywords

BISPHOSPHONATES; HIP FRACTURE; OSTEOPOROSIS

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG SAFETY; DRUG USE; FEMALE; FOOD AND DRUG ADMINISTRATION; HIP FRACTURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; UNITED STATES;

EID: 84979984804     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2832     Document Type: Article

References (20)

1. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Secondary Clinician's guide to prevention and treatment of osteoporosis; 2013. http://nof.org/files/nof/public/content/file/344/upload/159.pdf.
2. Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014; 29:1929–37. DOI:10.1002/jbmr.2202
3. Kim SC, Kim MS, Sanfelix-Gimeno G, et al. Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med. 2015; 128(5):519–26e1. DOI:10.1016/j.amjmed.2015.01.014
4. U.S. Food and Drug Administration. Safety Alerts for Human Medical Products − Aredia (pamidronate disodium), Zometa (zoledronic acid). Secondary Safety Alerts for Human Medical Products − Aredia (pamidronate disodium), Zometa (zoledronic acid) [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2005 [cited 2016 Mar 19]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150676.htm.
5. U.S. Food and Drug Administration. Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa) Information [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2015 Jul 8 [cited 2016 Mar 19]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm101551.htm.
6. Ulmner M, Jarnbring F, Torring O. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg. 2014; 72(1):76–82. DOI:10.1016/j.joms.2013.06.221
7. Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int. 2013; 24(1):237–44. DOI:10.1007/s00198-012-2042-6
8. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809–22. DOI:10.1056/NEJMoa067312
9. Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One. 2015; 10(4):e0122646. DOI:10.1371/journal.pone.0122646
10. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012; 27(12):2544–50. DOI:10.1002/jbmr.1719
11. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013; 28(8):1729–37. DOI:10.1002/jbmr.1893
12. Strom BL. Overview of automated databases in pharmacoepidemiology. In: Strom BL, Kimmel SE, editors. Textbook of pharmacoepidemiology. Philadelphia: John Wiley & Sons, Ltd; 2006. p. 167–72.
13. Ray W, Griffin M, Fought R, Adams M. Identification of fractures from computerized Medicare files. J Clin Epidemiol. 1992; 45(7):703–14.
14. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011; 64(7):749–59.
15. Eisman JA, Bogoch ER, Dell R, et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res. 2012; 27(10):2039–46. DOI:10.1002/jbmr.1698
16. Scaglione M, Fabbri L, Di Rollo F, Bianchi MG, Dell'omo D, Guido G. The second hip fracture in osteoporotic patients: not only an orthopaedic matter. Clin Cases Miner Bone Metab. 2013; 10(2):124–8.
17. Colon-Emeric C, Kuchibhatla M, Pieper C, et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int. 2003; 14(11):879–83. DOI:10.1007/s00198-003-1460-x
18. Lyles KW, Colon-Emeric CS, Magaziner JS, et al.; for the HORIZON Recurrent Fracture Trial. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med. 2007; 357: nihpa40967.
19. Bondo L, Eiken P, Abrahamsen B. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study. Osteoporos Int. 2013; 24(1):245–52. DOI:10.1007/s00198-012-2024-8
20. Black DM, Kelly MP, Genant HK, et al.; for the Fracture Intervention Trial and HORIZON Pivotal Fracture Trial Steering Committees. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010; 362(19):1761–71. DOI:10.1056/NEJMoa1001086